| 1st Oct 2025 3:00 pm |
RNS |
Total Voting Rights |
| 29th Sep 2025 7:30 am |
RNS |
Enhertu improved IDFS in early BC in DB-05 |
| 29th Sep 2025 7:00 am |
RNS |
AZN harmonises listing structure |
| 25th Sep 2025 4:30 pm |
RNS |
Director/PDMR Shareholding |
| 22nd Sep 2025 7:05 am |
RNS |
Koselugo recommended for EU approval |
| 22nd Sep 2025 7:00 am |
RNS |
Tezspire Recommended for Approval in EU for CRSwNP |
| 17th Sep 2025 7:05 am |
RNS |
Saphnelo met primary endpoint in TULIP-SC |
| 17th Sep 2025 7:00 am |
RNS |
Update on RESOLUTE Phase III trial |
| 1st Sep 2025 3:00 pm |
RNS |
Total Voting Rights |
| 28th Aug 2025 3:00 pm |
RNS |
Holding(s) in Company |
| 26th Aug 2025 3:00 pm |
RNS |
Holding(s) in Company |
| 21st Aug 2025 3:00 pm |
RNS |
Holding(s) in Company |
| 18th Aug 2025 3:00 pm |
RNS |
Director/PDMR Shareholding |
| 15th Aug 2025 3:00 pm |
RNS |
Holding(s) in Company |
| 12th Aug 2025 3:00 pm |
RNS |
Holding(s) in Company |
| 1st Aug 2025 3:00 pm |
RNS |
Total Voting Rights |
| 29th Jul 2025 7:00 am |
RNS |
H1 and Q2 2025 results |
| 24th Jul 2025 7:00 am |
RNS |
Gefurulimab nanobody met Phase III endpoints |
| 22nd Jul 2025 7:00 am |
RNS |
AstraZeneca plans to invest $50bn in the US |
| 16th Jul 2025 7:00 am |
RNS |
Update on anselamimab in AL amyloidosis |
| 14th Jul 2025 7:00 am |
RNS |
Baxdrostat met primary endpt in BaxHTN PhIII trial |
| 4th Jul 2025 7:00 am |
RNS |
Imfinzi approved in the EU for bladder cancer |
| 1st Jul 2025 3:00 pm |
RNS |
Total Voting Rights |
| 24th Jun 2025 7:00 am |
RNS |
Datroway approved in US for EGFRm lung cancer |
| 17th Jun 2025 11:45 am |
RNS |
Holding(s) in Company |
| 13th Jun 2025 9:30 am |
RNS |
AstraZeneca enters into collaboration with CSPC |
| 12th Jun 2025 3:00 pm |
RNS |
Director/PDMR Shareholding |
| 6th Jun 2025 7:00 am |
RNS |
Fixed-duration Calquence approved in EU for 1L CLL |
| 2nd Jun 2025 3:05 pm |
RNS |
Block listing Interim Review |
| 2nd Jun 2025 3:00 pm |
RNS |
Total Voting Rights |
| 27th May 2025 7:00 am |
RNS |
Imfinzi recommended in EU for bladder cancer |
| 23rd May 2025 10:00 am |
RNS |
Director/PDMR Shareholding |
| 21st May 2025 1:45 pm |
RNS |
Director Declaration |
| 20th May 2025 7:00 am |
RNS |
Acquisition of EsoBiotec completed |
| 9th May 2025 7:00 am |
RNS |
Imfinzi improved DFS in early bladder cancer |
| 7th May 2025 7:30 am |
RNS |
Enhertu improved pCR in early-stage breast cancer |
| 6th May 2025 7:00 am |
RNS |
Calquence combination approved in EU for 1L MCL |
| 2nd May 2025 7:00 am |
RNS |
Breztri met primary endpoints in Ph3 asthma trials |
| 1st May 2025 4:00 pm |
RNS |
Director/PDMR Shareholding |
| 1st May 2025 3:00 pm |
RNS |
Total Voting Rights |
